Treatment of experimental osteomyelitis by methicillin resistant Staphylococcus aureus with bone cement system

Nicolas Efstathopoulos1, Evangellos Giamarellos-Bourboulis, Kyriaki Kanellakopoulou

  • 1Athens University, 2nd Orthopaedic Department, Athens, Greece.

Injury
|July 29, 2008
PubMed

Insights

Local grepafloxacin in acrylic bone cement effectively treated experimental MRSA osteomyelitis in rabbits. This novel approach offers a promising alternative for bone infection treatment, potentially replacing current methods.

Area of Science:

  • Orthopedics
  • Infectious Diseases
  • Biomaterials Science

Background:

  • Chronic osteomyelitis caused by methicillin-resistant Staphylococcus aureus (MRSA) presents a significant treatment challenge.
  • Current treatments, such as gentamicin PMMA beads, have limitations.

Purpose of the Study:

  • To evaluate the efficacy of a local grepafloxacin-loaded acrylic bone cement (polymethyl methacrylate, PMMA) delivery system for treating experimental MRSA osteomyelitis.
  • To assess the safety and mechanical properties of the novel antibiotic-loaded cement.

Main Methods:

  • A rabbit model of chronic MRSA osteomyelitis was established.
  • Grepafloxacin (4%) was mixed with PMMA and implanted locally.
  • In vitro drug levels, clinical, radiographic, microbiological, histological, and biomechanical analyses were performed over 6 weeks.

Main Results:

  • Sustained high in vitro grepafloxacin levels were observed for 6 weeks.
  • No adverse tissue reaction to the cement was noted.
  • Progressive repair of osteomyelitis lesions and bone structure occurred post-implantation.
  • No significant negative impact on acrylic cement's mechanical properties was found.

Conclusions:

  • Local grepafloxacin-PMMA cement is effective and safe for treating MRSA osteomyelitis in this model.
  • This system shows potential as a replacement for gentamicin PMMA beads.
  • The method could also serve as a spacer in revision arthroplasty for infected prostheses.